Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback